10-Q Filing

REGENERON PHARMACEUTICALS, INC. CIK: 872589 Q2 2017

Filing Information

Form Type	10-Q
Accession Number	`0001532176-17-000027`
Period End Date	20170630
Filing Date	20170803
Fiscal Year	2017
Fiscal Period	Q2
XBRL Instance	regn-20170630.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 74 Income Statement 100 Cash Flow Statement 58

Balance Sheet 74 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$744.31M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$646.51M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$809.10M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$535.20M	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	30.00M	shares	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$503.48M	USD	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	30.00M	shares	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$523.54M	USD	Point-in-time
Accounts receivable - trade, net	`AccountsReceivableNetCurrent`	$1.42B	USD	Point-in-time
Accounts receivable - trade, net	`AccountsReceivableNetCurrent`	$1.34B	USD	Point-in-time
Preferred stock, shares issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Accounts Receivable from Sanofi	`AccountsReceivableRelatedPartiesCurrent`	$221.08M	USD	Point-in-time
Preferred stock, shares outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred stock, shares outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Accounts Receivable from Sanofi	`AccountsReceivableRelatedPartiesCurrent`	$92.99M	USD	Point-in-time
Accounts receivable from Bayer	`AccountsAndNotesReceivableNet`	$175.26M	USD	Point-in-time
Accounts receivable from Bayer	`AccountsAndNotesReceivableNet`	$203.07M	USD	Point-in-time
Inventories	`InventoryNet`	$554.32M	USD	Point-in-time
Inventories	`InventoryNet`	$399.36M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$193.33M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$130.53M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$3.18B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$3.86B	USD	Point-in-time
Treasury Stock, shares outstanding (in shares)	`TreasuryStockShares`	3.76M	shares	Point-in-time
Marketable securities	`MarketableSecuritiesNoncurrent`	$1.06B	USD	Point-in-time
Treasury Stock, shares outstanding (in shares)	`TreasuryStockShares`	3.76M	shares	Point-in-time
Marketable securities	`MarketableSecuritiesNoncurrent`	$864.26M	USD	Point-in-time
Property, Plant, and Equipment, Net	`PropertyPlantAndEquipmentNet`	$2.08B	USD	Point-in-time
Property, Plant, and Equipment, Net	`PropertyPlantAndEquipmentNet`	$2.26B	USD	Point-in-time
Deferred tax assets	`DeferredTaxAssetsLiabilitiesNetNoncurrent`	$825.30M	USD	Point-in-time
Deferred tax assets	`DeferredTaxAssetsLiabilitiesNetNoncurrent`	$882.98M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$20.29M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$36.96M	USD	Point-in-time
Total assets	`Assets`	$8.11B	USD	Point-in-time
Total assets	`Assets`	$6.97B	USD	Point-in-time
Accounts payable and accrued expenses	`AccountsPayableAndAccruedLiabilitiesCurrent`	$716.36M	USD	Point-in-time
Accounts payable and accrued expenses	`AccountsPayableAndAccruedLiabilitiesCurrent`	$879.10M	USD	Point-in-time
Capital and facility lease obligations, current	`Capitalandfacilityleaseobligationscurrent`	-	USD	Point-in-time
Capital and facility lease obligations, current	`Capitalandfacilityleaseobligationscurrent`	$129.56M	USD	Point-in-time
Deferred revenue from Sanofi, current portion	`DeferredRevenueFromRelatedPartyCurrent`	$184.45M	USD	Point-in-time
Deferred revenue from Sanofi, current portion	`DeferredRevenueFromRelatedPartyCurrent`	$115.27M	USD	Point-in-time
Deferred Revenue, Current	`DeferredRevenueCurrent`	$127.80M	USD	Point-in-time
Deferred Revenue, Current	`DeferredRevenueCurrent`	$116.40M	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$1.18M	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$397.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.24B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.03B	USD	Point-in-time
Capital and facility lease obligations	`Capitalandfacilityleaseobligationsnoncurrent`	$351.57M	USD	Point-in-time
Capital and facility lease obligations	`Capitalandfacilityleaseobligationsnoncurrent`	$701.17M	USD	Point-in-time
Deferred revenue from Sanofi	`DeferredRevenueFromRelatedPartyNoncurrent`	$443.90M	USD	Point-in-time
Deferred revenue from Sanofi	`DeferredRevenueFromRelatedPartyNoncurrent`	$503.47M	USD	Point-in-time
Deferred Revenue, Noncurrent	`DeferredRevenueNoncurrent`	$295.62M	USD	Point-in-time
Deferred Revenue, Noncurrent	`DeferredRevenueNoncurrent`	$327.30M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$115.92M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$100.39M	USD	Point-in-time
Total liabilities	`Liabilities`	$2.52B	USD	Point-in-time
Total liabilities	`Liabilities`	$2.59B	USD	Point-in-time
Preferred Stock	`PreferredStockValue`	-	USD	Point-in-time
Preferred Stock	`PreferredStockValue`	-	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$3.03B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$3.45B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$1.75B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$2.38B	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$2.35M	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-12.84M	USD	Point-in-time
Treasury stock	`TreasuryStockValue`	$316.24M	USD	Point-in-time
Treasury stock	`TreasuryStockValue`	$316.24M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$4.45B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$5.52B	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$8.11B	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$6.97B	USD	Point-in-time

Income Statement 100 line items

Line Item	Tag	Value	Unit	Period
Net product sales	`SalesRevenueGoodsNet`	$1.78B	USD	2 Qtrs
Net product sales	`SalesRevenueGoodsNet`	$1.62B	USD	2 Qtrs
Net product sales	`SalesRevenueGoodsNet`	$924.13M	USD	1 Quarter
Net product sales	`SalesRevenueGoodsNet`	$834.22M	USD	1 Quarter
Sanofi collaboration revenue	`RevenueFromRelatedParties`	$222.13M	USD	1 Quarter
Sanofi collaboration revenue	`RevenueFromRelatedParties`	$383.11M	USD	2 Qtrs
Sanofi collaboration revenue	`RevenueFromRelatedParties`	$163.41M	USD	1 Quarter
Sanofi collaboration revenue	`RevenueFromRelatedParties`	$432.50M	USD	2 Qtrs
Bayer Collaboration Revenue	`OtherCollaborationRevenue`	$404.29M	USD	2 Qtrs
Bayer Collaboration Revenue	`OtherCollaborationRevenue`	$210.35M	USD	1 Quarter
Bayer Collaboration Revenue	`OtherCollaborationRevenue`	$371.49M	USD	2 Qtrs
Bayer Collaboration Revenue	`OtherCollaborationRevenue`	$191.90M	USD	1 Quarter
Other revenue	`OtherSalesRevenueNet`	$113.50M	USD	1 Quarter
Other revenue	`OtherSalesRevenueNet`	$40.48M	USD	2 Qtrs
Other revenue	`OtherSalesRevenueNet`	$23.10M	USD	1 Quarter
Other revenue	`OtherSalesRevenueNet`	$169.94M	USD	2 Qtrs
Total revenues	`Revenues`	$1.21B	USD	1 Quarter
Total revenues	`Revenues`	$1.47B	USD	1 Quarter
Total revenues	`Revenues`	$2.79B	USD	2 Qtrs
Total revenues	`Revenues`	$2.41B	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$559.93M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$1.03B	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$509.98M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$1.02B	USD	2 Qtrs
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$603.75M	USD	2 Qtrs
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$306.91M	USD	1 Quarter
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$581.72M	USD	2 Qtrs
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$292.04M	USD	1 Quarter
Cost of goods sold	`CostOfGoodsSold`	$120.19M	USD	2 Qtrs
Cost of goods sold	`CostOfGoodsSold`	$103.39M	USD	2 Qtrs
Cost of goods sold	`CostOfGoodsSold`	$42.13M	USD	1 Quarter
Cost of goods sold	`CostOfGoodsSold`	$41.25M	USD	1 Quarter
Cost of collaboration and contract manufacturing	`Costofmanufacturing`	$83.70M	USD	2 Qtrs
Cost of collaboration and contract manufacturing	`Costofmanufacturing`	$27.79M	USD	1 Quarter
Cost of collaboration and contract manufacturing	`Costofmanufacturing`	$60.60M	USD	2 Qtrs
Cost of collaboration and contract manufacturing	`Costofmanufacturing`	$60.79M	USD	1 Quarter
Total expenses	`CostsAndExpenses`	$1.81B	USD	2 Qtrs
Total expenses	`CostsAndExpenses`	$919.80M	USD	1 Quarter
Total expenses	`CostsAndExpenses`	$1.79B	USD	2 Qtrs
Total expenses	`CostsAndExpenses`	$921.00M	USD	1 Quarter
Income from operations	`OperatingIncomeLoss`	$291.63M	USD	1 Quarter
Income from operations	`OperatingIncomeLoss`	$980.85M	USD	2 Qtrs
Income from operations	`OperatingIncomeLoss`	$550.31M	USD	1 Quarter
Income from operations	`OperatingIncomeLoss`	$620.94M	USD	2 Qtrs
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$5.36M	USD	2 Qtrs
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$1.88M	USD	1 Quarter
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$-19.06M	USD	1 Quarter
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$-9.81M	USD	2 Qtrs
Interest expense, net	`InterestIncomeExpenseNonoperatingNet`	$-5.40M	USD	1 Quarter
Interest expense, net	`InterestIncomeExpenseNonoperatingNet`	$-1.25M	USD	1 Quarter
Interest expense, net	`InterestIncomeExpenseNonoperatingNet`	$-3.89M	USD	2 Qtrs
Interest expense, net	`InterestIncomeExpenseNonoperatingNet`	$-12.90M	USD	2 Qtrs
Total other income (expense)	`NonoperatingIncomeExpense`	$-22.71M	USD	2 Qtrs
Total other income (expense)	`NonoperatingIncomeExpense`	$628.00K	USD	1 Quarter
Total other income (expense)	`NonoperatingIncomeExpense`	$-24.46M	USD	1 Quarter
Total other income (expense)	`NonoperatingIncomeExpense`	$1.47M	USD	2 Qtrs
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$622.41M	USD	2 Qtrs
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$958.14M	USD	2 Qtrs
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$525.85M	USD	1 Quarter
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$292.26M	USD	1 Quarter
Income tax expense	`IncomeTaxExpenseBenefit`	$321.46M	USD	2 Qtrs
Income tax expense	`IncomeTaxExpenseBenefit`	$138.11M	USD	1 Quarter
Income tax expense	`IncomeTaxExpenseBenefit`	$244.80M	USD	2 Qtrs
Income tax expense	`IncomeTaxExpenseBenefit`	$96.04M	USD	1 Quarter
Net income	`NetIncomeLoss`	$387.74M	USD	1 Quarter
Net income	`NetIncomeLoss`	$636.67M	USD	2 Qtrs
Net income	`NetIncomeLoss`	$377.60M	USD	2 Qtrs
Net income	`NetIncomeLoss`	$196.22M	USD	1 Quarter
Net income per share - basic	`EarningsPerShareBasic`	$3.66	USD	1 Quarter
Net income per share - basic	`EarningsPerShareBasic`	$3.61	USD	2 Qtrs
Net income per share - basic	`EarningsPerShareBasic`	$6.02	USD	2 Qtrs
Net income per share - basic	`EarningsPerShareBasic`	$1.88	USD	1 Quarter
Net income per share - diluted	`EarningsPerShareDiluted`	$3.34	USD	1 Quarter
Net income per share - diluted	`EarningsPerShareDiluted`	$1.69	USD	1 Quarter
Net income per share - diluted	`EarningsPerShareDiluted`	$3.24	USD	2 Qtrs
Net income per share - diluted	`EarningsPerShareDiluted`	$5.51	USD	2 Qtrs
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	106.03M	shares	1 Quarter
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	104.46M	shares	2 Qtrs
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	105.80M	shares	2 Qtrs
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	104.63M	shares	1 Quarter
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	116.14M	shares	1 Quarter
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	115.61M	shares	2 Qtrs
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	116.62M	shares	2 Qtrs
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	116.23M	shares	1 Quarter
Net income	`NetIncomeLoss`	$387.74M	USD	1 Quarter
Net income	`NetIncomeLoss`	$636.67M	USD	2 Qtrs
Net income	`NetIncomeLoss`	$377.60M	USD	2 Qtrs
Net income	`NetIncomeLoss`	$196.22M	USD	1 Quarter
Unrealized gain (loss) on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$840.00K	USD	1 Quarter
Unrealized gain (loss) on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$15.16M	USD	2 Qtrs
Unrealized gain (loss) on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-3.37M	USD	2 Qtrs
Unrealized gain (loss) on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$8.20M	USD	1 Quarter
Unrealized gain on cash flow hedges	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax`	$28.00K	USD	2 Qtrs
Unrealized gain on cash flow hedges	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax`	$28.00K	USD	1 Quarter
Unrealized gain on cash flow hedges	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax`	-	USD	2 Qtrs
Unrealized gain on cash flow hedges	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax`	-	USD	1 Quarter
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$374.24M	USD	2 Qtrs
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$197.06M	USD	1 Quarter
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$395.98M	USD	1 Quarter
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$651.86M	USD	2 Qtrs

Cash Flow Statement 58 line items

Line Item	Tag	Value	Unit	Period
Net income	`NetIncomeLoss`	$387.74M	USD	1 Quarter
Net income	`NetIncomeLoss`	$636.67M	USD	2 Qtrs
Net income	`NetIncomeLoss`	$377.60M	USD	2 Qtrs
Net income	`NetIncomeLoss`	$196.22M	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$73.24M	USD	2 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$48.01M	USD	2 Qtrs
Non-cash compensation expense	`ShareBasedCompensation`	$273.94M	USD	2 Qtrs
Non-cash compensation expense	`ShareBasedCompensation`	$255.05M	USD	2 Qtrs
Other non-cash charges and expenses, net	`OtherNoncashIncomeExpense`	$-7.79M	USD	2 Qtrs
Other non-cash charges and expenses, net	`OtherNoncashIncomeExpense`	$-37.63M	USD	2 Qtrs
Deferred taxes	`IncreaseDecreaseInDeferredIncomeTaxes`	$57.74M	USD	2 Qtrs
Deferred taxes	`IncreaseDecreaseInDeferredIncomeTaxes`	$162.65M	USD	2 Qtrs
Increase in Sanofi, Bayer, and trade accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$232.93M	USD	2 Qtrs
Increase in Sanofi, Bayer, and trade accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$284.18M	USD	2 Qtrs
Increase in Inventories	`IncreaseDecreaseInInventories`	$72.89M	USD	2 Qtrs
Increase in Inventories	`IncreaseDecreaseInInventories`	$151.54M	USD	2 Qtrs
(Increase) decrease in prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$77.17M	USD	2 Qtrs
(Increase) decrease in prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-57.09M	USD	2 Qtrs
Increase in deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$65.85M	USD	2 Qtrs
Increase in deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$-10.65M	USD	2 Qtrs
Increase in accounts payable, accrued expenses and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$133.93M	USD	2 Qtrs
Increase in accounts payable, accrued expenses and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-147.23M	USD	2 Qtrs
Total adjustments	`AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$66.89M	USD	2 Qtrs
Total adjustments	`AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$-311.34M	USD	2 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$325.33M	USD	2 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$444.49M	USD	2 Qtrs
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$477.41M	USD	2 Qtrs
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$228.94M	USD	2 Qtrs
Sales or maturities of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$102.18M	USD	2 Qtrs
Sales or maturities of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$272.17M	USD	2 Qtrs
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$242.93M	USD	2 Qtrs
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$105.31M	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-369.69M	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-310.55M	USD	2 Qtrs
Proceeds in connection with capital and facility lease obligations	`ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities`	-	USD	2 Qtrs
Proceeds in connection with capital and facility lease obligations	`ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities`	$57.00M	USD	2 Qtrs
Repayments of Long-term Debt, Long-term Capital Lease Obligations, and Capital Securities	`RepaymentsOfLongTermDebtAndCapitalSecurities`	$1.21M	USD	2 Qtrs
Repayments of Long-term Debt, Long-term Capital Lease Obligations, and Capital Securities	`RepaymentsOfLongTermDebtAndCapitalSecurities`	$19.93M	USD	2 Qtrs
Repayments of convertible senior notes	`RepaymentsOfConvertibleDebt`	$12.65M	USD	2 Qtrs
Repayments of convertible senior notes	`RepaymentsOfConvertibleDebt`	-	USD	2 Qtrs
Payments in connection with deduction of outstanding warrants	`PaymentsForRepurchaseOfWarrants`	-	USD	2 Qtrs
Payments in connection with deduction of outstanding warrants	`PaymentsForRepurchaseOfWarrants`	$242.12M	USD	2 Qtrs
Proceeds from issuance of Common Stock	`ProceedsFromIssuanceOfCommonStock`	$63.61M	USD	2 Qtrs
Proceeds from issuance of Common Stock	`ProceedsFromIssuanceOfCommonStock`	$188.69M	USD	2 Qtrs
Payments in connection with Common Stock tendered for employee tax obligations	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$31.44M	USD	2 Qtrs
Payments in connection with Common Stock tendered for employee tax obligations	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$45.01M	USD	2 Qtrs
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-237.39M	USD	2 Qtrs
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$194.33M	USD	2 Qtrs
Net increase (decrease) in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-162.59M	USD	2 Qtrs
Net increase (decrease) in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$209.11M	USD	2 Qtrs
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$744.31M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$646.51M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$809.10M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$535.20M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$744.31M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$646.51M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$809.10M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$535.20M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.